Oak Stone Limited Comments On Nestle As They Agree To Acquire Allergy Treatment Maker Aimmune For $2.6 Billion

The offer gives the California-based biopharmaceutical a company valuation of $2.6 billion, which includes the $473 million that Nestle had previously invested in Aimmune, according to data collected …
( read original story …)


Search your Hotel